Outpatient Management of COVID-19: Rapid Evidence Review

Anthony Cheng, MD; Dominic Caruso, MD, MPH; and Craig McDougall, MD
Oregon Health & Science University, Portland, Oregon

Common presenting symptoms of coronavirus disease 2019 include fever, dry cough, shortness of breath, and fatigue. However, patients may have a wide range of symptoms representing a spectrum of mild to severe illness. Symptoms in children tend to be milder and may include fever, cough, and feeding difficulty. The incubation period is two to 14 days, although symptoms typically appear within five days of exposure. Multiple testing modalities exist, but infection should be confirmed by polymerase chain reaction testing using a nasopharyngeal swab. There are no evidence-based treatments appropriate for use in the outpatient setting; management is supportive and should include education about isolation. In hospitalized patients, remdesivir should be considered to reduce time to recovery, and low-dose dexamethasone should be considered in patients who require supplemental oxygen. Overall, 85% of patients have mild illness, whereas 14% have severe disease requiring hospitalization, including 5% who require admission to an intensive care unit. Predictors of severe disease include increasing age, comorbidities, lymphopenia, neutrophilia, leukocytosis, low oxygen saturation, and increased levels of C-reactive protein, d-dimer, transaminases, and lactate dehydrogenase. (Am Fam Physician. 2020;102:online. Copyright © 2020 American Academy of Family Physicians.)

Published online September 22, 2020.

The coronavirus disease 2019 (COVID-19) pandemic is caused by an enveloped single-stranded RNA novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first cases were reported in Wuhan City, China, in December 2019; the United States confirmed its first cases one month later. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome, also caused by coronaviruses, have caused significantly lower global mortality.

Epidemiology

- The basic reproductive number (infections per index case) of COVID-19 is unknown. One systematic review estimated a range of 1.9 to 6.5.¹
- Studies in the United States and Switzerland based on antibody sampling estimated seroprevalence between 1.1% and 10.9%.²
- Pathogenic factors contributing to the virulence of SARS-CoV-2 include transmissibility via respiratory droplets and asymptomatic spread via healthy-appearing individuals.
- The true incidence of COVID-19 in the United States is unknown and varies geographically.³
- It is estimated that only one in approximately 80 COVID-19 infections was diagnosed in March 2020, and there is promise in disease modeling that extrapolates from influenza-like illness.⁴

Screening and Prevention

- Physical distancing of at least 6 ft (1.8 m) slows the spread of infection by decreasing the mean number of people infected per case, particularly when combined with other measures such as mask wearing in public, school closures, and travel restrictions.⁵,⁶
- Contact tracing has reduced the spread of infection early during outbreaks in some countries.⁷
- The Centers for Disease Control and Prevention (CDC) recommends that close contacts of a person with COVID-19 quarantine for 14 days after the last exposure and monitor for fever and other symptoms daily.⁸ People suspected of having COVID-19 should isolate within their home to prevent infection spread, stay in a specific “sick room” if they live with others, and use a separate bathroom, if possible.⁹

CME credit for this article will be available when it is published in print.

Author disclosure: No relevant financial affiliations.

Patient information: A handout on this topic is available at https://familydoctor.org/condition/coronavirus.
COVID-19

• The CDC recommends wearing face masks when in a public space where appropriate physical distancing may be difficult. This practice may reduce viral transmission (Howard J, et al., and Kai D, et al., unpublished data, 2020), particularly from asymptomatic or presymptomatic individuals.

• Patients with respiratory symptoms should wear a surgical mask in health care settings. Those without respiratory symptoms should wear a cloth face mask per CDC recommendations.

• Table 1 lists recommended personal protective equipment for clinicians based on different clinical scenarios.

• A vaccine for SARS-CoV-2 has not yet been deployed, but more than 100 are in development and 36 are in clinical evaluation. Although other vaccines do not protect against SARS-CoV-2 infection, routine vaccinations are still recommended.

Diagnosis

• The diagnosis of COVID-19 is made clinically and is supported by laboratory results and radiographic findings. COVID-19 should be suspected in patients with known or suspected exposure within the past 14 days, or in the setting of active SARS-CoV-2 transmission in the community.

<table>
<thead>
<tr>
<th>Clinical recommendation</th>
<th>Evidence rating</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient without respiratory symptoms</td>
<td>C</td>
<td>Expert opinion based on disease modeling</td>
</tr>
<tr>
<td>Patient with respiratory symptoms</td>
<td>C</td>
<td>Expert opinion in the absence of clinical trials</td>
</tr>
<tr>
<td>Collection of nasal swab in patient with suspected or confirmed infection*</td>
<td>C</td>
<td>Expert opinion and cross-sectional studies of diagnostic accuracy</td>
</tr>
<tr>
<td>Non–aerosol-generating procedure</td>
<td>C</td>
<td>Expert opinion</td>
</tr>
<tr>
<td>Aerosol-generating procedure†</td>
<td>B</td>
<td>Two RCTs, one of which was positive and one of which was negative but underpowered</td>
</tr>
</tbody>
</table>

COVID-19 = coronavirus disease 2019; NNT = number needed to treat; RCT = randomized controlled trial.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Equipment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient without respiratory symptoms</td>
<td>Standard precautions, surgical masks, and eye protection</td>
</tr>
<tr>
<td>Patient with respiratory symptoms</td>
<td>Surgical mask, gown, gloves, and eye protection</td>
</tr>
<tr>
<td>Collection of nasal swab in patient with suspected or confirmed infection*</td>
<td>N95 or higher-level respirator (or surgical mask if respirator is not available), eye protection, gloves</td>
</tr>
<tr>
<td>Non–aerosol-generating procedure</td>
<td>Surgical mask, face shield, gown, and gloves¹⁴</td>
</tr>
<tr>
<td>Aerosol-generating procedure†</td>
<td>N95 or powered air-purifying respirator, eye protection, isolation gown, gloves</td>
</tr>
</tbody>
</table>

*—Institutional guidelines vary. See reference 11 for more information. If respirators are not readily available, they should be prioritized for use during other procedures with higher risk of producing infectious aerosols.

†—Any medical procedure that can convert a physical substance into particles small and light enough to be carried by air, such as nebulizer treatment, cardiopulmonary resuscitation, high-flow nasal oxygen, sputum induction, chest physiotherapy, bilevel or continuous positive airway pressure, endotracheal intubation, airway suction, high-frequency oscillatory ventilation, tracheostomy, or bronchoscopy.

Information from references 11-14.
When possible, patients should be triaged via telehealth before they receive in-person care (Figure 1).17

Physicians should be aware of anchoring bias when considering a diagnosis of COVID-19. Given the wide variability in presentations, it should be considered as one among several potential etiologies.

The differential diagnosis includes:
- Acute pulmonary edema
- Acute respiratory distress syndrome
- Chronic obstructive pulmonary disease exacerbation
- Community-acquired pneumonia (bacterial or viral)
- Influenza
- Interstitial lung disease
- Nonspecific viral upper respiratory tract infection
- Opportunistic pulmonary infection
- Pulmonary embolism
- Streptococcal pharyngitis

**SIGNS AND SYMPTOMS**

- The incubation period of SARS-CoV-2 is two to 14 days, although symptoms generally appear within five days of exposure.18

- Common presenting symptoms include fever, dry cough, shortness of breath, and fatigue19; however, patients may have a wide range of symptoms representing a spectrum of mild to severe illness (Table 2).20-29
- Moderate to severe anosmia and altered taste are commonly reported.24
- Symptoms in children tend to be milder than in adults and may include fever, cough, and feeding difficulty (Arnaout R, et al., unpublished data, 2020).21
- Pregnant and recently pregnant women are less likely to present with fever and myalgias compared with nonpregnant patients of reproductive age.30
- A high proportion of patients with SARS-CoV-2 infection (about 40%) are asymptomatic, particularly younger patients.31
- Multisystem inflammatory syndrome in children is thought to be related to COVID-19. Signs include prolonged fever and clinically severe illness with multiorgan involvement. The diagnosis is supported by laboratory confirmation of inflammation, evidence of recent SARS-CoV-2

**FIGURE 1**

Algorithm for telehealth triage of patients with diagnosed or suspected COVID-19.

*Information from reference 17.*

<table>
<thead>
<tr>
<th>Likely COVID-19; patient is well or has only mild symptoms</th>
<th>Self-management</th>
<th>Offer testing</th>
<th>Arrange close follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Likely COVID-19; patient has moderate symptoms</td>
<td>Refer for in-person visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient has moderate to severe symptoms with red flags</td>
<td>Refer for in-person visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient has symptoms or comorbidities that make COVID-19 diagnosis uncertain (e.g., congestive heart failure, chronic obstructive pulmonary disease)</td>
<td>Refer to emergency department</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 2**

**Signs and Symptoms of Coronavirus Disease 2019**

**Adults**
- Anosmia or altered taste (64%)
- Fever (56% to 99%)
- Cough (55% to 82%)
- Anorexia (40%)
- Fatigue (38% to 70%)
- Sputum production (27% to 34%)
- Shortness of breath (19% to 57%)
- Chills (12% to 15%)
- Myalgias (11% to 45%)
- Dizziness (8% to 9%)
- Sore throat (5% to 14%)
- Headache (3% to 14%)
- Diarrhea (2% to 24%)
- Chest pain (2% to 15%)
- Nasal congestion or rhinorrhea (2% to 5%)
- Rash or skin discoloration (1% to 20%)
- Nausea and vomiting (1% to 19%)
- Hemoptysis (1% to 2%)
- Conjunctivitis (1%)

**Children**
- Pharyngeal erythema (46%)
- Cough (44% to 54%)
- Fever (41% to 56%)
- Diarrhea (8%)
- Fatigue (8%)
- Rhinorrhea (8%)
- Vomiting

*Information from references 20-29.*
The PCR test detects the presence of coronavirus RNA and is used to confirm diagnosis of COVID-19. Positive results do not rule out bacterial infection or coinfection with other viruses. Sensitivity varies depending on time from symptom onset, so results should be interpreted based on clinical and epidemiologic factors. Nasopharyngeal swabs are somewhat more sensitive than oropharyngeal swabs. If both are collected, they may be combined and tested simultaneously in a single reaction to conserve reagents. Reliability is unknown because there is no standard diagnostic test, there are multiple test types, production methods are inconsistent, and implementation varies around the world. Extrapolating from data on PCR tests for influenza, the PCR rapid test for COVID-19 may be highly specific (90% to 95%), meaning a positive result is good at ruling out infection, but only moderately sensitive (50% to 70%), meaning a negative result does not reliably rule out infection (Arnaout R, et al., unpublished data, 2020). A negative result should be taken in the context of other symptoms, exposures, and the clinical presentation to guide recommendations. 

<table>
<thead>
<tr>
<th>Type of test</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibody test</td>
<td>The antibody test is most useful for epidemiologic purposes and in children with multisystem inflammatory syndrome to provide evidence of current or past COVID-19 infection. It detects the presence of IgM and IgG antibodies to SARS-CoV-2, which emerge approximately five and 14 days after symptom onset, respectively (Wajnberg A, et al., unpublished data, 2020). A positive result can indicate prior infection or exposure, which is important for detecting infections with few or no symptoms. Early evidence suggests that most patients develop a vigorous antibody response to SARS-CoV-2, but it is not known if this correlates with resistance to future infection. Results should not be used as the sole basis on which to diagnose or exclude SARS-CoV-2 infection. A positive result may be due to current or past infection with non–SARS-CoV-2 coronavirus strains. Even tests with good specificity can yield more false-positive than true-positive results when population prevalence is low.</td>
</tr>
<tr>
<td>PCR test</td>
<td>The PCR test detects the presence of coronavirus RNA and is used to confirm the diagnosis of COVID-19. Positive results do not rule out bacterial infection or coinfection with other viruses. Sensitivity varies depending on time from symptom onset, so results should be interpreted based on clinical and epidemiologic factors. Nasopharyngeal swabs are somewhat more sensitive than oropharyngeal swabs. If both are collected, they may be combined and tested simultaneously in a single reaction to conserve reagents. Reliability is unknown because there is no standard diagnostic test, there are multiple test types, production methods are inconsistent, and implementation varies around the world. Extrapolating from data on PCR tests for influenza, the PCR rapid test for COVID-19 may be highly specific (90% to 95%), meaning a positive result is good at ruling in infection, but only moderately sensitive (50% to 70%), meaning a negative result does not reliably rule out infection (Arnaout R, et al., unpublished data, 2020). A negative result should be taken in the context of other symptoms, exposures, and the clinical presentation to guide recommendations.</td>
</tr>
<tr>
<td>Point-of-care tests</td>
<td>Results are available within minutes. Nucleic acid amplification testing targets part of the RdRp gene that is specific to SARS-CoV-2. Antigen testing uses antibodies and immunofluorescence to detect the presence of SARS-CoV-2. The reliability, sensitivity, and specificity of these tests are variable.</td>
</tr>
</tbody>
</table>

COVID-19 = coronavirus disease 2019; Ig = immunoglobulin; PCR = polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. Information from references 2 and 34-42.

infection, or exposure and no other obvious microbial cause of inflammation. There are multiple testing modalities for COVID-19 (Table 3). Acute infection should be confirmed with polymerase chain reaction testing using a nasopharyngeal swab. Antibody testing is most useful for epidemiologic purposes. Point-of-care testing provides rapid results, but the reliability of these tests is not clear. The decision to test depends on variables such as availability of test kits and reagents, and implications for treatment, infection control, and public health. In addition to patients with signs or symptoms of COVID-19, testing should be considered for patients who: Have a known or suspected exposure (including neonates born to a mother diagnosed with COVID-19) Will undergo a planned surgery or aerosol-generating procedure Are undergoing chemotherapy Are part of a group disproportionately affected by COVID-19, such as Black, Latino, Pacific Islander, or American Indian/Alaska Native communities. • Testing asymptomatic people after an exposure is recommended five to seven days after the exposure based on the median viral incubation period. Testing should not occur for at least 48 hours after exposure. Asymptomatic contacts with negative test results still must quarantine for 14 days. Retesting can be considered to confirm disease resolution in immunocompromised patients if enough testing capacity exists. • Radiographic findings in patients with COVID-19 may include: “Crazy paving” (i.e., ground-glass opacity with superimposed interlobular and intralobular septal thickening) Dense consolidation

| Antibody test | The antibody test is most useful for epidemiologic purposes and in children with multisystem inflammatory syndrome to provide evidence of current or past COVID-19 infection. It detects the presence of IgM and IgG antibodies to SARS-CoV-2, which emerge approximately five and 14 days after symptom onset, respectively (Wajnberg A, et al., unpublished data, 2020). A positive result can indicate prior infection or exposure, which is important for detecting infections with few or no symptoms. Early evidence suggests that most patients develop a vigorous antibody response to SARS-CoV-2, but it is not known if this correlates with resistance to future infection. Results should not be used as the sole basis on which to diagnose or exclude SARS-CoV-2 infection. A positive result may be due to current or past infection with non–SARS-CoV-2 coronavirus strains. Even tests with good specificity can yield more false-positive than true-positive results when population prevalence is low. |
| PCR test | The PCR test detects the presence of coronavirus RNA and is used to confirm the diagnosis of COVID-19. Positive results do not rule out bacterial infection or coinfection with other viruses. Sensitivity varies depending on time from symptom onset, so results should be interpreted based on clinical and epidemiologic factors. Nasopharyngeal swabs are somewhat more sensitive than oropharyngeal swabs. If both are collected, they may be combined and tested simultaneously in a single reaction to conserve reagents. Reliability is unknown because there is no standard diagnostic test, there are multiple test types, production methods are inconsistent, and implementation varies around the world. Extrapolating from data on PCR tests for influenza, the PCR rapid test for COVID-19 may be highly specific (90% to 95%), meaning a positive result is good at ruling in infection, but only moderately sensitive (50% to 70%), meaning a negative result does not reliably rule out infection (Arnaout R, et al., unpublished data, 2020). A negative result should be taken in the context of other symptoms, exposures, and the clinical presentation to guide recommendations. |
| Point-of-care tests | Results are available within minutes. Nucleic acid amplification testing targets part of the RdRp gene that is specific to SARS-CoV-2. Antigen testing uses antibodies and immunofluorescence to detect the presence of SARS-CoV-2. The reliability, sensitivity, and specificity of these tests are variable. |

COVID-19 = coronavirus disease 2019; Ig = immunoglobulin; PCR = polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. Information from references 2 and 34-42.

TESTING

- There are multiple testing modalities for COVID-19 (Table 3). Acute infection should be confirmed with polymerase chain reaction testing using a nasopharyngeal swab. Antibody testing is most useful for epidemiologic purposes. Point-of-care testing provides rapid results, but the reliability of these tests is not clear. The decision to test depends on variables such as availability of test kits and reagents, and implications for treatment, infection control, and public health. In addition to patients with signs or symptoms of COVID-19, testing should be considered for patients who:
  - Have a known or suspected exposure (including neonates born to a mother diagnosed with COVID-19)
  - Will undergo a planned surgery or aerosol-generating procedure
  - Are undergoing chemotherapy
  - Are part of a group disproportionately affected by COVID-19, such as Black, Latino, Pacific Islander, or American Indian/Alaska Native communities.

- Testing asymptomatic people after an exposure is recommended five to seven days after the exposure based on the median viral incubation period. Testing should not occur for at least 48 hours after exposure. Asymptomatic contacts with negative test results still must quarantine for 14 days.
- Retesting can be considered to confirm disease resolution in immunocompromised patients if enough testing capacity exists.
- Radiographic findings in patients with COVID-19 may include: “Crazy paving” (i.e., ground-glass opacity with superimposed interlobular and intralobular septal thickening) Dense consolidation

- Ground-glass opacity
- Multifocal ground-glass opacity
- In hospitalized patients, the following laboratory tests can help assess prognosis and identify patients at risk of vascular and thrombotic complications: Complete blood count with differential C-reactive protein level
COVID-19

- d-dimer assay
- Lactate dehydrogenase level
- Troponin level

Treatment
- There are no evidence-based treatments for COVID-19 that are appropriate for use in the outpatient setting; management is supportive.41
  - The World Health Organization recommends that infants born to women with COVID-19 not be separated from their mothers, and that these mothers initiate and continue breastfeeding.44
  - Remote patient monitoring via telehealth can be used to detect red flag symptoms that warrant urgent assessment, such as:17:
    - Fever above 100.4°F (38°C)
    - Heart rate greater than 100 beats per minute with new confusion
    - Oxygen saturation less than 95%
    - Respiratory rate greater than 20 breaths per minute
- Figure 2 shows a protocol for discontinuing home isolation after COVID-19 diagnosis.11,45

DRUG THERAPY
- In addition to supportive care, there are several investigational drugs being explored for the treatment of COVID-19 in hospitalized patients.
  - Dexamethasone, 6 mg per day for 10 days, significantly reduced mortality in hospitalized patients with COVID-19 who required supplemental oxygen (number needed to treat [NNT] = 29) or mechanical ventilation (NNT = 9), but not in hospitalized patients who did not require...
supplemental oxygen. Systemic corticosteroids are not recommended for outpatients or for hospitalized patients who do not require supplemental oxygen.

- Remdesivir (Veklury) was shown in a U.S. randomized trial to significantly reduce time to recovery (11 vs. 15 days) and to nonsignificantly reduce mortality (7.1% vs. 11.9%; \( P = .059 \)) in hospitalized patients with COVID-19. A Chinese study found no significant benefit, but the study was underpowered. Remdesivir has not been studied in outpatients with nonsevere illness and is not recommended for this population.

- Hydroxychloroquine (Plaquenil) has not been shown to have clear benefit in patients with mild to severe COVID-19 symptoms, or for postexposure prophylaxis (Horby P, et al., unpublished data, 2020).

- There is insufficient evidence to recommend the use of the following treatments for COVID-19:
  - Azithromycin (Zithromax)
  - Convalescent plasma
  - Interferon
  - Ivermectin (Soolantra)
  - Lopinavir/ritonavir (Kaletra)
  - Ribavirin (Virazole)
  - Tocilizumab (Actemra)

**REFERRAL, CONSULTATION, AND HOSPITALIZATION**

- In the course of an in-person assessment, the appropriate disposition of patients with symptomatic COVID-19 can be guided by vital signs, physical examination findings, respiratory rate, oxygen saturation, social considerations, and risk factors as outlined in Figure 3.

**Prognosis**

- International data suggest that 85% of people with COVID-19 have only mild illness, whereas 14% have severe disease requiring hospitalization, including 5% of adults and 2% of children who require admission to an intensive care unit. Children tend to have a better prognosis than adults (Arnaout R, et al., unpublished data, 2020).

- The overall mortality rate from COVID-19 has been estimated to be 0.66% to 0.9%, although estimates are difficult because of the number of undiagnosed cases. Observed rates vary considerably (2.3% to 7.2%) depending on location and test availability. As of July 21, 2020, the Johns Hopkins Center for Health Security reported a U.S. case fatality rate of 3.7%. Case fatality rates increase with age.

- Predictors of more severe disease or death include clinical factors, comorbidities, and laboratory findings (Table 4).

Common risk factors in hospitalized patients include:

- Cardiovascular disease
- Chronic kidney disease
- Chronic liver disease
- Chronic obstructive pulmonary disease
- Diabetes mellitus
- Hypercholesterolemia
- Hypertension
- Malignancy

---

**FIGURE 3**

Algorithm for in-person evaluation of patients with diagnosed or suspected symptomatic coronavirus disease 2019.

Information from references 11, 17, 44, 54, and 55.
The risk of these complications include:

- Acute respiratory distress syndrome, stroke, and arterial and venous thrombosis. Hospitalized patients may have debility.
- Preterm birth and preterm prematurity rupture of membranes. The risk of vertical transmission and risks to newborns are not well understood.
- In pregnant women, COVID-19 may increase the risk of premature birth, preterm prematurity, and rupture of membranes. The risk of vertical transmission and risks to newborns are not well understood.

### TABLE 4

**Risk Factors for Severe Illness in Adults with COVID-19**

<table>
<thead>
<tr>
<th>Clinical factors</th>
<th>Comorbidities</th>
<th>Laboratory findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body mass index ≥ 30 kg per m²</td>
<td>Blood disorders (e.g., sickle cell disease, patient taking blood thinners)</td>
<td>Elevated C-reactive protein, lactate dehydrogenase, alanine transaminase, aspartate transaminase, or dimer level</td>
</tr>
<tr>
<td>Dyspnea, increased respiratory rate, decreased oxygen saturation</td>
<td>Chronic kidney disease</td>
<td>Leukocytosis</td>
</tr>
<tr>
<td>Male sex</td>
<td>Chronic liver disease</td>
<td>Low albumin level</td>
</tr>
<tr>
<td>Older age*</td>
<td>Chronic lung disease (e.g., chronic obstructive pulmonary disease, asthma)</td>
<td>Lymphopenia</td>
</tr>
<tr>
<td>Current or recent (within two weeks) pregnancy</td>
<td>Endocrine disorders (e.g., diabetes mellitus)</td>
<td>Neutrophilia</td>
</tr>
<tr>
<td>Heart disease (e.g., congestive heart failure, coronary artery disease, hypertension)</td>
<td>Heart disease (e.g., congestive heart failure, coronary artery disease, hypertension)</td>
<td>Neutrophilia</td>
</tr>
<tr>
<td>Immunosuppression (e.g., autoimmune disease, malignancy, HIV infection)</td>
<td>Neurologic or neurodevelopmental conditions</td>
<td></td>
</tr>
</tbody>
</table>


*—Among adults 65 to 84 years of age who are diagnosed with COVID-19, 31% to 59% are hospitalized, 11% to 31% are admitted to the ICU, and 4% to 11% die. Among adults 85 years and older who are diagnosed with COVID-19, 31% to 70% are hospitalized, 10% to 27% are admitted to the ICU, and 10% to 27% die.17

Information from references 37 and 61-64.

### TABLE 5

**Additional COVID-19 Resources**

- BMJ’s COVID-19 hub
  - [https://www.bmj.com/coronavirus](https://www.bmj.com/coronavirus)
- European Centre for Disease Prevention and Control: contact tracing for COVID-19
- Infectious Diseases Society of America: COVID-19 treatment guidelines
- National Institutes of Health: COVID-19 treatment guidelines
  - [https://www.covid19treatmentguidelines.nih.gov](https://www.covid19treatmentguidelines.nih.gov)
- World Health Organization: interim guidance on clinical management of COVID-19


- A diet with inadequate fruits and vegetables (Adams ML, et al., unpublished data, 2020)
- Body mass index greater than 40 kg per m²
- Sedentary lifestyle
- Smoking

- The long-term health effects of COVID-19 are under investigation.
- Approximately 35% of people with COVID-19 have not returned to their previous level of health 14 to 21 days after diagnosis. These “long haulers” have a syndrome referred to as long COVID.68
- Table 5 lists additional COVID-19 resources for clinicians.

**Data Sources:** An initial evidence review was performed by the COVID Inquiry Group of the Oregon Health & Science University School of Medicine. Search terms included COVID, COVID-19, and SARS-CoV2. Answers were reviewed by two faculty reviewers. A subsequent literature review was performed using PubMed, Essential Evidence Plus, and the COVID-19 Daily Research Briefs on the AFP website. Search dates: March through September 2020.

This article was based on the Outpatient COVID-19 Reference Guide published in April 2020 by the Oregon Health & Science University (OHSU). The project lead was Jessica Hoyt; other contributors included Johanna Warren, MD; Dominic Caruso, MD; Anthony Cheng, MD; Eric Herman, MD; Debbie Lambberger, MPA; Craig McDougall, MD; Andy Barnett, MD; Daisuke Yamashita, MD; and Emily Barclay, MS. We wish to acknowledge the work of the OHSU COVID Lab Task Force and the OHSU School of Medicine COVID Inquiry Group: co-leads Frances Biagioli, MD, and Kam Pierce, MPA; core faculty members Heather Angier, PhD; Amy Chen, MD; Elizabeth Haney, MD; and Glenn Rodriguez, MD; core student group Hannah Bacheller, Eva Davis, Brett Lewis, Asma Lotfi, Lauren Raymond, Elizabeth Swanson, and Kanwarabijit Thind; contributing authors Brooke...
Bachelor, DO; Andrea Baron, MPH; Kathryn Bonuck, MS; Elizabeth Bower, MD; Annie Buckmaster, MD; Dominic Caruso, MD; Anthony Cheng, MD; Joshua Cohen, MD; Roopradha Datta, MPH; Shelby Lee Freed, FNP; Natalie Freitas, MD; Laurel Hallock-Koppelman, DNP; Cassandra Kasten-Arias; Roheet Kakada, MD; Christine Le, MD; Justin Lewis, MD; Ingrid Lindquist, MD; Morgan Lisner, MD; Mustafa Mahmood, MD; Brittany McAdams, MD; Craig McDougall, MD; John Mitchell, MD; Laurence Moore, MD; Cassie Mullen, MD; Ryan Nesbit, MD; Kristen Otto, MD; Gina Philippi; Megan Quinlan, MD; Sean Robinson, MD; Whitney Roper, MD; Eric Schmidt, MD; Linh Taylor; Erin Urbanowicz; Eric Wiser, MD; Jean Yau, MD; and Hirofumi Yoshida, MD.

The Authors

ANTHONY CHENG, MD, is the associate residency director and an assistant professor in the Department of Family Medicine at Oregon Health & Science University, Portland.

DOMINIC CARUSO, MD, MPH, is chief resident in the Department of Family Medicine at Oregon Health & Science University.

CRAIG McDOUGALL, MD, is the medical director and an assistant professor in the Division of General Internal Medicine and Geriatrics at Oregon Health & Science University.

Address correspondence to Anthony Cheng, MD, Oregon Health & Science University, 3303 SW Bond Ave., Portland, OR 97239 (email: chengan@ohsu.edu). Reprints are not available from the authors.

References


COVID-19


